طول کامل ماده از گلوکوکورتیکوئید های سیستمیک متناوب با دوز بالا و خطر شکستگی در بیماران مبتلا به بیماری مزمن انسدادی ریه

Intermittent high-dose GCs was not associated with an increased risk of any, osteoporotic, hip or clinically symptomatic vertebral fractures in patients with COPD. Current GC use was however associated with an increased risk of hip and clinically symptomatic vertebral fractures. Therefore, emphasis on prophylactic treatment of fractures may not be essential in patients with COPD receiving intermittent dose of GCs, whereas this should be considered for high-dose long-term users with advanced COPD disease stage, postmenopausal women and men over 40 years.